DK3398946T3 - Salt af morpholin-derivat og krystallin form deraf, samt fremstillingsfremgangsmåde, farmaceutisk sammensætning og anvendelse af samme - Google Patents

Salt af morpholin-derivat og krystallin form deraf, samt fremstillingsfremgangsmåde, farmaceutisk sammensætning og anvendelse af samme Download PDF

Info

Publication number
DK3398946T3
DK3398946T3 DK16881245.1T DK16881245T DK3398946T3 DK 3398946 T3 DK3398946 T3 DK 3398946T3 DK 16881245 T DK16881245 T DK 16881245T DK 3398946 T3 DK3398946 T3 DK 3398946T3
Authority
DK
Denmark
Prior art keywords
salt
well
pharmaceutical composition
same
crystalline form
Prior art date
Application number
DK16881245.1T
Other languages
Danish (da)
English (en)
Inventor
Guangxin Xia
Jianshu Xie
Guohui Jia
Jiansheng Han
Naoko Ueda
Toru Iijima
Original Assignee
Shanghai Pharmaceuticals Holding Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Pharmaceuticals Holding Co Ltd filed Critical Shanghai Pharmaceuticals Holding Co Ltd
Application granted granted Critical
Publication of DK3398946T3 publication Critical patent/DK3398946T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/33—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems
    • C07C309/34—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems formed by two rings
    • C07C309/35—Naphthalene sulfonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/42—Separation; Purification; Stabilisation; Use of additives
    • C07C51/43—Separation; Purification; Stabilisation; Use of additives by change of the physical state, e.g. crystallisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/08—Acetic acid
    • C07C53/10—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK16881245.1T 2015-12-29 2016-12-29 Salt af morpholin-derivat og krystallin form deraf, samt fremstillingsfremgangsmåde, farmaceutisk sammensætning og anvendelse af samme DK3398946T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201511016783 2015-12-29
PCT/CN2016/112966 WO2017114456A1 (zh) 2015-12-29 2016-12-29 吗啉衍生物的盐及其晶型、其制备方法及药物组合物、用途

Publications (1)

Publication Number Publication Date
DK3398946T3 true DK3398946T3 (da) 2022-08-08

Family

ID=59224612

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16881245.1T DK3398946T3 (da) 2015-12-29 2016-12-29 Salt af morpholin-derivat og krystallin form deraf, samt fremstillingsfremgangsmåde, farmaceutisk sammensætning og anvendelse af samme

Country Status (11)

Country Link
US (1) US10519150B2 (cg-RX-API-DMAC10.html)
EP (1) EP3398946B1 (cg-RX-API-DMAC10.html)
JP (1) JP6818031B2 (cg-RX-API-DMAC10.html)
CN (3) CN113816951B (cg-RX-API-DMAC10.html)
DK (1) DK3398946T3 (cg-RX-API-DMAC10.html)
ES (1) ES2918674T3 (cg-RX-API-DMAC10.html)
HU (1) HUE059444T2 (cg-RX-API-DMAC10.html)
PL (1) PL3398946T3 (cg-RX-API-DMAC10.html)
PT (1) PT3398946T (cg-RX-API-DMAC10.html)
TW (1) TWI705065B (cg-RX-API-DMAC10.html)
WO (1) WO2017114456A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022047730A1 (en) * 2020-09-04 2022-03-10 Shanghai Pharmaceuticals Holding Co., Ltd. Methods to treat inflammatory bowel disease
KR102898913B1 (ko) * 2020-09-04 2025-12-10 상하이 파마슈티컬스 홀딩 컴퍼니 리미티드 질소 함유 포화 헤테로사이클릭 화합물의 응용
CN116425677B (zh) * 2022-01-11 2026-04-14 苏州恩华生物医药科技有限公司 氨基环丁烷衍生物的盐、其晶型及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL150524A0 (en) * 2000-01-07 2003-02-12 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
EP2687518B1 (en) * 2011-03-16 2017-11-01 Mitsubishi Tanabe Pharma Corporation Nitrogen-containing saturated heterocyclic compound
JP5764628B2 (ja) * 2012-09-14 2015-08-19 田辺三菱製薬株式会社 医薬組成物
WO2014042263A1 (ja) * 2012-09-14 2014-03-20 田辺三菱製薬株式会社 新規レニン阻害薬

Also Published As

Publication number Publication date
CN113816951A (zh) 2021-12-21
CN106928218B (zh) 2021-08-03
ES2918674T3 (es) 2022-07-19
CN106928218A (zh) 2017-07-07
EP3398946A1 (en) 2018-11-07
PL3398946T3 (pl) 2022-10-10
TWI705065B (zh) 2020-09-21
PT3398946T (pt) 2022-08-09
WO2017114456A1 (zh) 2017-07-06
US10519150B2 (en) 2019-12-31
US20190016718A1 (en) 2019-01-17
EP3398946A4 (en) 2019-08-28
EP3398946B1 (en) 2022-05-04
JP6818031B2 (ja) 2021-01-20
TW201722950A (zh) 2017-07-01
JP2019500385A (ja) 2019-01-10
CN113816951B (zh) 2022-09-27
HUE059444T2 (hu) 2022-11-28
CN113816952A (zh) 2021-12-21

Similar Documents

Publication Publication Date Title
IL286428A (en) Disubstituted heterocyclyl derivatives as inhibitors of cyclin-dependent kinases
IL254124A0 (en) New 3-indole-transformed histories, medicinal preparations and methods of use
IL268852A (en) Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan
HUE042449T2 (hu) Új 4-metoxi-pirrolszármazékok vagy sóik és az azokat tartalmazó gyógyászati készítmények
HUE058009T2 (hu) 1,3-Tiazol-2-il szubsztituált benzamid-származékok
LT3513809T (lt) Medicininė kompozicija, apimanti tivozanibą
LT3371190T (lt) Heterocikliniai junginiai, kaip pi3k-gama inhibitoriai
HUE059158T2 (hu) Eljárás pridopidin elõállítására
HUE057876T2 (hu) Biciklusos-kondenzált heteroaril- vagy aril-vegyületek és ezek IRAK4 inhibitorként történõ alkalmazása
EP3579957A4 (en) POLYHALITE GRANULATION PROCESS
DK3497081T3 (da) Fremgangsmåde til fremstilling af 4-ammonium-2,2,6,6-tetraalkylpiperidinylsalte
DK3429998T6 (da) Fremgangsmåde til fremstilling af quinolin-2-yl-phenylaminderivater og disses salte
IL252089A0 (en) 2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors
HUE050974T2 (hu) Eljárás pirimidinszulfamid-származékok elõállítására
DK3255042T3 (da) Heterocyklisk forbindelse og farmaceutisk sammensætning omfattende samme
DK3164123T3 (da) Hidtil ukendte anvendelser af benzylidenguanidinderivater til behandling af proteopatier
HUE055463T2 (hu) Eljárás glükopiranozil-szubsztituált benzil-benzol-származékok elõállítására
DK3278801T3 (da) Farmaceutisk sammensætning indeholdende mirabegron
HUE052833T2 (hu) Eljárás 2,5-furándikarbonsav (FDCA) elõállítására
IL287119B1 (en) Bryostatin compounds and methods of preparing the same
HUE050553T2 (hu) Eljárás A módosulatú kalkobutrol kristályos alakjának elõállítására
IL259234B (en) Cephem compounds, their production and use
DK3390412T3 (da) Vandopløselige derivater af 3,5-diphenyl-diazolforbindelser
LT3389633T (lt) Farmacinės kompozicijos, apimančios fenilaminopirimidino darinį
DK3169405T3 (da) Fremgangsmåder, forbindelser og sammensætninger til behandling af muskel- og skeletsygdomme